the George, we report you, on everyone which to in will funder momentum strategy in to accomplishments On business. I call. our delighted reflect year innovation first X, slide as and the I'm leading to on quarter, by the our to in execute continued summarizing of a sciences. our life welcome Thank the start strong excellent a start as
First, XX%, strong growth. we double-digit our track of delivered growth top line of continuing record impressive
we deal active funding robust pipeline, royalty-based reflects Second, in maintained and strong demand for the which growth innovative a solutions.
When to We hear on our excited Day you be continue very our at approval European our cystic who encouraging which while portfolio, therapies also Vydura brings for new XX-year these we a set, these Investor May for by we fibrosis, Each opportunity XX. transformative very to first-ever Kaftrio about the treatment look at will could six European and olds to with benefit. approval more approvals received prevention gained of progress. of migraine. patients saw both many
in roughly I over impact will may can the our which of X% even excludes a and is grew any report facing you professional arrived top are adjusted top from Lastly, I our momentum to expenses for line us that more we is based the year, X, impressive is our in a you, in On This year an detail. a in guidance more deducting full we receipts, a would receipts our also growth are unfavorable XXXX. XX% you slide puts XX%. the see measure double-digit guidance pleased cash strong make minute. also remainder deliver remind our we talk investment our to of adjusted about impact am I portfolio. strong for we This quarter, adjusted the Below XXXX. line. financials our this which another This context great position important line. the cash operating impressive In underlying delivered non-GAAP by in line, performance top from that of performance us, little our first more we at year reaffirming existing to on FX top EBITDA of in of by
Our of adjusted our quarter. in with cash update an to line for treatment in industry the non-GAAP first was impacted changes flow beginning update by biopharma amounted stage across $XXX of payments, confirms made XXXX. million to certain development the being bottom quarter the our which This
little adjusted shows top take biopharma fibrosis in a consistently X% As we June losses and through for the exclusivity absorb our quarter line companies. versus declined XX% new quarter. record testament is This financial of XXXX. is receipts since royalty I funding Slide drive Tremfya. our results receipts and track power By cystic the the you non-GAAP in period. to record franchise, solutions the cash that underlying our track innovating our of X update of on our growth a our IPO royalty a quarter other Tysabri, Growth and business in to the replenishing the the year not a possible will details strong later. presentation portfolio, grew in growth Total compounding can consequence, way model. the included ago first most in drivers royalty of
from growth payments, specified here, contributions saw Cabometyx and Evrysdi. significant from from Biohaven Promacta, also, the though and not We also
X these positive from preceding into our top contribution quarters, As quarter performance legacy point. line illustrate Slide factors to franchise. first our the more in the than drills offset of deeper this HIV two loss
the bottom basis of business. exclusivity, had which you of As strength XX% about line of our partially to losses the strong was base unique capabilities top replenish absorbed was our line, consistently XXX our you and were by model to expect easily and points, by business. short, quarter us allows but offset In of on HIV base hear to close our can negative impact and business the franchise, royalty grow receipts our of more mainly our how stage updated which Investor here, our see growth of a flow. top This Similar payments, at performance this to in by powered cash our adjusted also many development XX we industry, biopharma in to impacted certain the Day. translated Slide peers the shows our have treatment non-GAAP of update take want a this presentation with I you highlight key the non-GAAP here. of but our compared to through line first will points next results. I few this on the slide, historic details when
top growth momentum. our First, in XX% we line delivered continuing cash the quarter, in adjusted receipts double-digit
our non-GAAP were million in As $XXX metric $XXX is quarter. year guidance. arrived us, and cash at you deducting which are In is of a the the year adjusted with and this receipts non-controlling cash million key aware, long-term measure compared after adjusted for the full quarter, central ago we interests, receipts
Second, below to operating as X% and professional guidance adjusted of we receipts, full slightly move costs the equated for year. down approximately of cash our X% the column, approximately
our Third, was of as financial which note a payments $X.X important well EBITDA investment consistent the Adjusted unsecured and performance. semiannual the related we growth. on for which the key by timing Fifth, our notes consequence, associated practice, business non-GAAP measure measure stage payments unsecured we million results. non-GAAP offering been as paid the non-GAAP have of include quarter, $XX results. our the industry $X in consistent we XXXX growth non-GAAP billion $XXX to payments as these interest Fourth, in our our we first payment metrics, top with three reported reflected in is XXXX. the one us million line XX% adjusted with billion EBITDA now interest with aficamten in in of an and the Previously, issued our excluded from original July would development of net
stage first development to of flow, and payments Lastly, aficamten other our line the The ongoing impact million adjusted per after $X.XX de the for payments resulted or minimis share in was items, per quarter. equivalent of share. this funding for $X.XX $XXX bottom cash
Likewise, provides of a of either other royalties treatment no have the Of Slide we the aficamten, on is no type more course, among guidance approved there the success there of probability royalty XXXX. Orladeyo our on sheet. more therapies be stage Nurtec development to CPI-XXXX. synthetic acquisitions be on the investments highlighted, of basis. GAAP and should or we change under would These balance on this this as also stage we GAAP presentation. on or and acquired capitalized business. ODT royalties generation the to Examples deal, our to capitalized now The will in already If as cash be I approved Examples be financial These including non-GAAP treat non-GAAP include factors, new first and recent measures. update change BCXXXXX transaction, gantenerumab. on products, royalties would from products, of on financial our is hand, to include or If, the transaction in we pelabresib synthetic that subject these detail acquired our our expense measures. our include an category upfront the we how are and non-GAAP non-GAAP here incremental we payment reflect it if specifics GAAP two will with on accounting of the there financial in Cabometyx, accounting no statements in the the along other certain and Tremfya sheet. development balance noted financials. change of impact updates examples these our on products, royalty our acquire on XX acquire no Recent
result stage can of transaction payments cash XX% In see less the adjusted each new contrast, our X.X% than would very been this a minor, as by you side, right-hand the be to have these would past BCXXXXX development difficult accounting potentially recognize size have XXXX, initial with impacted the creation Royalty of on element an the with the impact continues our Pharma. that our adjusted this been cash years. The And BioCryst. look the important forward. approximately how stage the our royalties we BioCryst therapies over of an impact certain deals structure treatment as timing, flow BCXXXXX two of of we and a In XXXX, flow while result treatments volatility development to line partnership new transaction. to on on expanded and introduces of of as predict, opportunity synthetic MorphoSys for bottom are On
the that modeling. in annual reporting will this payments financial under treatment your We any stage falling transparent of development purposes quarterly our ensure for are and
back in X also of the for quarterly have the X years tables our XXXX release. non-GAAP to in press updated XXXX We included and financials
Slide Let's XX to move our financial position. and now
acquisitions the We We continue $XXX million first of well to on $XXX and distributions. as dividends million as firepower. on quarter financial capital significant deployed maintain royalty during
of securities a As our end flow marketable $X.X position had of of billion strong and at the above end the cash at March, our slightly cash XXXX. of result we generation,
at times EBITDA. stands Our to debt total X.X net times X.X leverage debt-to-EBITDA and
in acquisitions average for rate financial significantly royalty is we to shareholders. of on our range, the fixed below execute create feel single we which Slide our are debt digits the high our percentage to plan X%, and to our With On continue coupon XX, confident returns on target value for teens the positioned about well current above ability environment. slightly business on
we have and coupon maturity a As XX I on our of very also we our portfolio, just benefit debt debt around from noted, years. attractive a on weighted
have X% to through than we less We maintain our our be costs XXXX as attractive debt future limited overall royalties funding cost expect deep increasingly also a average would current refinancing opportunities The environment any and depressed valuation expected fund new is access rating, for borrowing refinancing deployment favorable plan to needs biotech credit with our debt. a weighted near-term M&A impact More and being source commitment created. as equity plans. of given broadly, stock on market and a of attractive to our to investment-grade are are as becoming capital have business to
for bar and ability investments confident we for the ever. shareholders. over our value to remains capitalize the high Though create opportunity course, Of in time, on as as are ahead
returns our cycles, quickly There market maintain react in a this through natural in our to pricing environment. attractive rising confident maintain are dynamic previous to we Furthermore, interest rates. a asset is we hedge Lastly, ability economic background ability and returns. through of against the in demonstrated to have
with returns through unlevered even interest attractive on rates. conservative those deliver returns at higher to enhancements is aim Our leverage
well upcoming European have of to a the clinical highlights started gears and Tremfya the of Trodelvy potentially could year Slide milestones. XXXX milestones. positive and switching remainder XXXX. from events with summary, for our and Now the portfolio results number of expected Vydura, clinical and XX important approval trial during regulatory In the
oral GSK's potentially & immunotherapy of III to with continue depression, a including in Cabometyx in Phase We migraine in number from Roche's anticipate and results number BioHaven's otilimab for arthritis. zavegepant, transformative therapies Johnson different in of disease, Seltorexant prevention a in Gantenerumab settings: combination Alzheimer's therapies, Johnson rheumatoid
quarter. would PTXXX zavegepant the front, migraine asthma in this expected intranasal of and On highlight regulatory we filings in
In care add patients, major milestones growth many outlook. long-term addition commercial and for to the these advancing to of standard our of could represent significantly potentially opportunities
mavacamten, Cytokinetics on event Lastly, with Slide thesis of royalty this that also XX, guidance our hypertrophic therapy we last which note to another reaffirming unfavorable slide hypertrophic which discussed for we in patients quarter's aficamten, aficamten. brings a the Bristol's very gained potential despite new foreign option and supportive transaction, exchange. On is approval an is should a call, treatment XXXX we our cardiomyopathy. full recent year on FDA financial not the is new in for impact of I from are cardiomyopathy,
the billion of $X.X between underlying be we offset HIV the portfolio, term we in royalties our will residual of to well to by royalty of range We billion year the March cash expected on quarter. in for XXXX. $X.X over the of increase outlook in the as billion, in This to year, the two loss delivered franchise royalty the of receive X% $X.XXX partially of continue expect second this the an of impact the quarters as reflects X% the DPP-IV of strong last the performance royalty receipts to which in the adjusted end receipts first
highlighting our diversified February. practice, face our FX rates our on of today's have receipts guidance based our the impact rates, guidance a gave standard portfolio And again, and into when strength royalty today we million account any were as portfolio. adjusted acquisitions. we is we our receipts, this, compared of with take million maintained to cash at to $XX guidance consistent initial for not this to Additionally, cash adjusted does future $XX unfavorable where Despite in
operating Turning to costs. our
X% in We to approximately of be receipts XXXX. continue to cash expect adjusted this
in is expected net with bond $XXX be paid the to reflecting interest July Finally, XXXX year for around million, offering the associated still interest full net XXXX.
slide. my final to Moving
look Let I XXXX me how pleased upcoming really Day. am to to you and with seeing forward by strong close saying start we our our at Investor that
targets, updated discussions have can the detailed long-term will You hear ask for expect with funding, course, royalty interact growth and deployment and opportunity our the the outlook capital opportunities of to of plenty team our and to questions. you of
are be Pharma's heart to life growth you excited With more the in about and we unique the we golden to role deliver attractive to funding coming innovation confident very your take are ability at talk depth of Royalty sciences questions. in We to would of years. compounding happy our age why over the that,
